Corporate News

Grant of Options

24 January 2017

Further to the announcement on 11 November 2016, Quantum Pharma plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that, upon his commencing employment with the Company on 23 January 2017, it granted options over 1,100,000 Ordinary Shares of 10 pence each ('Ordinary Shares') with an exercise price of 30 pence, to Gerard Murray, Chief Financial Officer.

The options represent approximately 0.65% of the current issued share capital and are in accordance with the rules of the Quantum Long Term Incentive Plan ('LTIP') 2014 as amended by the Remuneration Committee. The options shall vest and become exercisable at an exercise price of 30 pence, either on the mid-market closing share price being greater than 140 pence for an average of 90 days or on a change of control. The options shall lapse if the target has not been achieved on or before 31 December 2021 and the exercise period runs from the vesting date until 9 November 2026.

Following this award, Gerard Murray has an interest in 200,000 Ordinary Shares and options over 1,100,000 Ordinary Shares, representing 0.12% and 0.65% respectively of the current share capital.

Following the above LTIP grant and other recent grants of LTIP options (on the same terms as above) and lapses of existing LTIP options, there are outstanding options over 15,940,438 Ordinary Shares, representing approximately 9.43% of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Gerard Murray
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Quantum Pharma Plc
b) LEI (Pending)
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Options over Ordinary Shares of £0.10 QP. ISIN: GB00BRTL8Q42
b) Nature of the transaction Grant of options
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil paid, exercise price of 30 pence 1,100,000
d) Aggregated information
- Aggregated volume
- Price
N/A - single transaction
e) Date of the transaction 23 January 2017
f) Place of the transaction n/a
d) Aggregated information
- Aggregated volume
- Price

N/A - single transaction
e) Date of the transaction 23 January 2017
f) Place of the transaction Off market


For further information:

Quantum Pharma Plc  
Chris Rigg, CEO Tel: +44 (0) 1207 279 404
Gerard Murray, CFO  
Craig Swinhoe, Group Strategic Projects Director and Company Secretary
N+1 Singer (NOMAD and Broker) Tel: +44 (0) 20 7496 3000
Sandy Fraser / Nick Owen / James White
Media enquiries:  
Henry Harrison-Topham / Sophie Cowles / Steph Watson Tel: +44 (0) 20 7466 5000


Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions - Specials, Niche Pharmaceuticals and Medication Adherence – offering a portfolio of innovative and complementary products and services.

For further information, please visit


back to top

back to Takeover Code


Quantum Pharmaceuticals
UL Medicines
Quantum Aseptics
PERN Consumer Products